7/31/2013

The FDA granted priority-review status to Vanda Pharmaceuticals' regulatory application for tasimelteon, an experimental treatment for blind people with the non-24-hour disorder. If approved, tasimelteon will be the first drug cleared for the condition. A decision is expected by Jan. 31.

Full Story:
Bloomberg

Related Summaries